Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trialMaria Pouyiourou, Alwin Krämer, Boris Kubuschok et al.|Nature Communications|2023Cited by 36
738P Combined ipilimumab and nivolumab in previously treated patients with cancer of unknown primary: Results of the CheCUP trialMaria Pouyiourou, A. Krämer, Bianca Kraft et al.|Annals of Oncology|2022Cited by 3